1. Home
  2. TGNA vs ARQT Comparison

TGNA vs ARQT Comparison

Compare TGNA & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TEGNA Inc

TGNA

TEGNA Inc

HOLD

Current Price

$19.54

Market Cap

3.2B

Sector

Industrials

ML Signal

HOLD

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

HOLD

Current Price

$27.74

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGNA
ARQT
Founded
1906
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
3.3B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
TGNA
ARQT
Price
$19.54
$27.74
Analyst Decision
Buy
Strong Buy
Analyst Count
4
7
Target Price
$20.00
$24.83
AVG Volume (30 Days)
1.7M
2.0M
Earning Date
11-10-2025
10-28-2025
Dividend Yield
2.56%
N/A
EPS Growth
N/A
N/A
EPS
2.10
N/A
Revenue
$2,876,414,000.00
$317,929,000.00
Revenue This Year
N/A
$85.51
Revenue Next Year
$11.10
$30.74
P/E Ratio
$9.30
N/A
Revenue Growth
N/A
129.21
52 Week Low
$14.87
$11.13
52 Week High
$21.35
$31.77

Technical Indicators

Market Signals
Indicator
TGNA
ARQT
Relative Strength Index (RSI) 47.17 47.41
Support Level $19.58 $28.30
Resistance Level $19.80 $31.77
Average True Range (ATR) 0.19 1.14
MACD 0.03 -0.57
Stochastic Oscillator 65.28 5.80

Price Performance

Historical Comparison
TGNA
ARQT

About TGNA TEGNA Inc

Tegna Inc is a media company with a portfolio of broadcast stations and digital sites. The firm has television stations and radio stations in approximately U.S. markets. The company owns multicast networks of True Crime Network, Twist, and Quest. Each television station also has a robust digital presence across online, mobile, connected television, and social platforms, reaching consumers on all devices and platforms used to consume news content. It generates key revenue from advertising and marketing services, subscriptions, political advertising, and other services.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Share on Social Networks: